Pinnacle Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$58.4M Buy
485,756
+39,496
+9% +$4.56M 0.75% 26
2025
Q4
$47M Buy
446,260
+3,144
+0.7% +$295K 0.6% 33
2025
Q3
$37.2M Buy
443,116
+292
+0.1% +$24.1K 0.49% 45
2025
Q2
$35.1M Sell
442,824
-549
-0.1% -$43.6K 0.51% 46
2025
Q1
$39.8M Sell
443,373
-25,530
-5% -$2.38M 0.58% 32
2024
Q4
$46.6M Sell
468,903
-5,162
-1% -$532K 0.63% 28
2024
Q3
$51.7M Buy
474,065
+13,301
+3% +$1.58M 0.88% 20
2024
Q2
$57M Sell
460,764
-9,338
-2% -$1.2M 0.89% 21
2024
Q1
$62M Sell
470,102
-3,963
-0.8% -$488K 0.98% 17
2023
Q4
$51.7M Sell
474,065
-1,091
-0.2% -$113K 0.87% 20
2023
Q3
$48.9M Sell
475,156
-3,900
-0.8% -$420K 0.91% 15
2023
Q2
$55.3M Buy
479,056
+44,092
+10% +$5.01M 0.96% 12
2023
Q1
$46.3M Sell
434,964
-23,132
-5% -$2.5M 0.95% 17
2022
Q4
$50.8M Sell
458,096
-13,558
-3% -$1.39M 1.11% 8
2022
Q3
$40.6M Sell
471,654
-4,342
-0.9% -$388K 0.93% 14
2022
Q2
$43.4M Sell
475,996
-23,456
-5% -$2.08M 0.95% 13
2022
Q1
$41M Buy
499,452
+8,231
+2% +$649K 0.73% 31
2021
Q4
$37.6M Buy
491,221
+36,355
+8% +$2.9M 0.65% 38
2021
Q3
$34.2M Buy
454,866
+17,430
+4% +$1.33M 0.63% 41
2021
Q2
$34M Sell
437,436
-8,949
-2% -$666K 0.62% 41
2021
Q1
$32.8M Buy
446,385
+34,930
+8% +$2.58M 0.63% 42
2020
Q4
$32.1M Sell
411,455
-5,497
-1% -$420K 0.65% 37
2020
Q3
$33M Sell
416,952
-6,910
-2% -$541K 0.78% 28
2020
Q2
$31.3M Sell
423,862
-11,085
-3% -$834K 0.77% 28
2020
Q1
$31.9M Buy
434,947
+24,626
+6% +$1.94M 0.97% 17
2019
Q4
$35.6M Sell
410,321
-41,635
-9% -$3.42M 0.78% 28
2019
Q3
$36.3M Sell
451,956
-117,942
-21% -$9.45M 0.86% 23
2019
Q2
$45.6M Sell
569,898
-4,282
-0.7% -$328K 1.07% 16
2019
Q1
$45.6M Sell
574,180
-32,331
-5% -$2.42M 1.03% 17
2018
Q4
$44.2M Sell
606,511
-37,110
-6% -$2.62M 1.14% 14
2018
Q3
$43.6M Buy
643,621
+111,215
+21% +$7.09M 0.9% 22
2018
Q2
$30.8M Sell
532,406
-28,592
-5% -$1.61M 0.63% 45
2018
Q1
$29.2M Sell
560,998
-2,620
-0.5% -$142K 0.57% 47
2017
Q4
$30.3M Buy
563,618
+36,667
+7% +$2.03M 0.58% 51
2017
Q3
$32.2M Sell
526,951
-11,760
-2% -$713K 0.59% 48
2017
Q2
$32.9M Buy
538,711
+347
+0.1% +$21.1K 0.63% 43
2017
Q1
$32.6M Sell
538,364
-3,243
-0.6% -$197K 0.62% 41
2016
Q4
$30.4M Sell
541,607
-36,666
-6% -$2.15M 0.61% 42
2016
Q3
$34.4M Buy
578,273
+6,736
+1% +$394K 0.69% 39
2016
Q2
$31.4M Sell
571,537
-5,285
-0.9% -$281K 0.68% 37
2016
Q1
$29.1M Sell
576,822
-14,685
-2% -$719K 0.62% 41
2015
Q4
$29.8M Buy
591,507
+84,171
+17% +$4.24M 0.63% 41
2015
Q3
$23.9M Sell
507,336
-5,730
-1% -$304K 0.53% 55
2015
Q2
$27.9M Buy
513,066
+4,714
+0.9% +$264K 0.52% 52
2015
Q1
$27.9M Sell
508,352
-5,269
-1% -$298K 0.52% 52
2014
Q4
$27.8M Buy
513,621
+1,435
+0.3% +$80K 0.55% 46
2014
Q3
$29M Sell
512,186
-3,102
-0.6% -$174K 0.59% 42
2014
Q2
$28.4M Sell
515,288
-6,257
-1% -$341K 0.56% 49
2014
Q1
$28.3M Sell
521,545
-26,438
-5% -$1.37M 0.55% 49
2013
Q4
$26.2M Sell
547,983
-32,649
-6% -$1.49M 0.51% 54
2013
Q3
$26.4M Buy
580,632
+4,515
+0.8% +$206K 0.55% 48
2013
Q2
$25.5M Buy
+576,117
New +$25.7M 0.57% 46

Other funds holding MRK

Pinnacle Associates's MRK Position: Q1 2026 in Review

Pinnacle Associates increased its Merck (MRK) stake by 8.9% in Q1 2026, buying an estimated $4.56M and bringing the position to 485,756 shares worth $58.4M. The position accounts for 0.75% of the portfolio, ranked #26.

Pinnacle Associates first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $62M in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Pinnacle Associates held 485,756 shares of Merck worth $58.4M as of Q1 2026.
  • Pinnacle Associates bought 39,496 Merck shares in Q1 2026, an estimated $4.56M.
  • Merck made up 0.75% of Pinnacle Associates's portfolio in Q1 2026, its #26 holding.
  • Pinnacle Associates first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Pinnacle Associates's Merck position peaked at $62M in Q1 2024.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Pinnacle Associates's 13F filing for Q1 2026, filed 22 Apr 2026.